Global Health Limited trimmed its FY26 net loss by 12.5% to A$758,220, driven by a 5.5% lift in recurring SaaS revenue and a 20% cut in employee costs aided by AI integration, though going concern risks remain.
- Net loss reduced 12.5% to A$758K
- Annual Recurring Revenue up 5.5% to A$6.67M
- Employee costs down 20% through AI adoption
- EBITDA loss improves 28% to A$545K
- Material uncertainty flagged on going concern
Losses Narrow as SaaS Revenue Climbs
Global Health Limited (ASX:GLH) posted a modest improvement in its financial results for the year ended 30 June 2026, cutting its net loss by 12.5% to A$758,220. Revenue from ordinary activities slipped 1.8% to A$7.18 million, but the picture brightens when focusing on the company’s subscription-based software-as-a-service (SaaS) platforms, which saw Annual Recurring Revenue (ARR) rise 5.5% to A$6.674 million, now representing 93% of customer revenue.
The rise in SaaS revenue was underpinned by a 14.2% increase in ARR subscriptions to A$2.05 million, accounting for 31% of total ARR. This growth was supported by over 30 new and existing clients adopting platforms such as MasterCare Plus, HotHealth Digital Front Door, and ReferralNet Secure Messaging, reflecting ongoing demand for digital healthcare solutions.
Cost Discipline and AI Drive Profitability Gains
Global Health’s operating expenses, including research and development, fell 9% to A$8.58 million, despite some upticks in corporate costs like audit and rent. The company credits significant efficiency gains from adopting artificial intelligence (AI) across its operations, which slashed employee and contractor costs by A$1.35 million or 20% compared to the prior year. This included one-off redundancy costs of A$136,234.
The cost savings translated into a 28% improvement in EBITDA (after fully expensed R&D), narrowing the loss to A$545,000 from A$760,000 the year before. Gross margins on recurring revenue doubled to 50%, up from 38% in FY25, highlighting the benefits of transitioning to a SaaS-heavy model with automated onboarding and training.
Strategic AI Integrations and Product Enhancements
Global Health is embedding AI not just internally but also within its product suite. The company launched AI Assistants in its MasterCare platforms to support end-users and partnered with Heidi Health to integrate clinical scribe and decision support AI for clinicians. Internally, an AI receptionist is nearing deployment to handle inbound calls efficiently, while an AI-powered avatar within the LifeCard Personal Health Record platform aims to empower consumers with personalised health coaching.
Additionally, the company unveiled a productivity platform leveraging agentic AI to streamline workflows and reporting across its software ecosystem. These initiatives align with management's FY27 plan to double the customer acquisition team and accelerate revenue growth through AI-enabled efficiencies and new SaaS offerings.
Balance Sheet and Going Concern Considerations
Despite operational improvements, Global Health remains in a net liability position with net tangible liabilities per share at (6.38) cents, slightly improved from (7.57) cents the prior year. Cash reserves halved to A$738,065, and the current ratio fell to 0.67, reflecting tight liquidity.
The auditor issued an unqualified opinion but highlighted a material uncertainty related to going concern, citing the company’s net liability position and cash flow constraints. The directors remain confident the Group can meet obligations through ongoing cost control, expected R&D tax incentives of approximately A$700,000, and potential additional funding, including convertible notes maturing in mid-2027.
Convertible Notes and Equity Incentives
Global Health has 846,000 convertible notes on issue with a 12% coupon and maturity in June to August 2027. The company redeemed 100,000 notes early during FY26. Directors hold 50,000 notes each. The notes include embedded derivatives valued through Monte Carlo simulations due to conversion features.
On the equity front, the company issued 1.8 million performance rights to employees under its Equity Incentive Plan, subject to non-market service and performance hurdles. No short-term incentive bonuses were paid to executives in FY26 as EBITDAR targets were not met.
Outlook Hinges on Execution of Growth Strategy
Looking ahead, Global Health aims to leverage its AI-enhanced SaaS platforms to drive revenue growth, targeting approximately A$2 million from new business in FY27. The company plans to expand its customer acquisition efforts and continue embedding AI to boost productivity and client onboarding efficiency.
However, the going concern uncertainty flagged by auditors underscores the execution risk inherent in this strategy, particularly the need to convert pipeline growth into sustainable cash flow and manage debt maturities effectively. Investors will be watching closely how the company balances growth ambitions with financial discipline in the year ahead.
Bottom Line?
Global Health’s improved SaaS traction and AI-driven cost cuts have trimmed losses, but its net liability position and tight cash flow keep going concern risks firmly in play.
Questions in the middle?
- Can Global Health convert its AI initiatives and SaaS pipeline into consistent positive cash flow in FY27?
- What is the company’s plan to manage convertible notes maturing in mid-2027 without dilutive equity raises?
- How will competitive pressures in healthcare software impact Global Health’s ability to grow recurring revenue?